GlaxoSmithKline Recalls H1N1 Vaccine in Canada Over ‘Life-Threatening’ Allergy Risk
News outlets are reporting this morning that the pharmaceutical giant GlaxoSmithKline is advising medical personnel in Canada that one of its batches of H1N1 flu vaccine may trigger a life-threatening allergy.
A GlaxoSmithKline spokesperson, Gwenan White, is quoted as saying the recall was issued after determining that one batch of H1N1 vaccine may be responsible for more allergic reactions than what is being seen with other batches.
The identified batch consists of 172,000 doses of the H1N1 vaccine. The spokesperson declined to divulge how many doses had already been administered before the recall was issued.
